Drugs / TRPH-222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03682796 | Oct 2018 → Nov 2021 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Triphase Research and Development III Corp. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRPH-222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682796 ↗ |
| Known as | Anti-cd22 adc trph-222 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594508 ↗ |
| Modality | Other / unclassified | “Antibody-Drug Conjugate” NCT03682796 ↗ |
| Route | Intravenous | “administered by IV, 21-day Cycle” NCT03682796 ↗ |